A5082291642- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Statistical Methods in Clinical Trials
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Biosimilars and Bioanalytical Methods
- Cancer-related gene regulation
- Glioma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- SARS-CoV-2 and COVID-19 Research
- Hepatitis C virus research
- Cancer Treatment and Pharmacology
Université Paris-Saclay
2016-2025
Institut Gustave Roussy
2016-2025
Assistance Publique – Hôpitaux de Paris
2013-2024
Inserm
2017-2024
Sorbonne Université
2023
Laboratoire d'études sur les monothéismes
2023
École Normale Supérieure
2023
Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne
2023
Pitié-Salpêtrière Hospital
2023
Bicêtre Hospital
2012-2021
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible vulnerability PD-1 blockade. The phase Ib study KEYNOTE-013 (NCT01953692) tested safety and efficacy anti–PD-1 antibody pembrolizumab in patients with hematologic malignancies. Based on its genetics, HL was included as an independent cohort. Methods We enrolled relapsed or refractory whose disease progressed after treatment...
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as rare but potentially severe event. Between December 2015 and April 2016, we conducted retrospective study in centres experienced ICI use. We report the main features ICI–ILD with focus on clinical presentation, radiological patterns therapeutic strategies. 64 (3.5%) out 1826 cancer patients...
Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.
Abstract The circulating metabolome provides a snapshot of the physiological state organism responding to pathogenic challenges. Here we report alterations in plasma reflecting clinical presentation COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), critical (in intensive care). This analysis revealed major disease- stage-associated shifts metabolome, meaning that at least 77 metabolites including...
Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall (OS) and complete pathological response (pCR) cancer types both early metastatic approaches. However, distinct spectrum toxicities between cytotoxic side effects immune related adverse events (irAEs) similar clinical presentations different management strategies remains a challenge daily practice...
Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers.This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (NCT02082977). Doses GSK2816126 ranged from 50 to 3,000 mg twice weekly, was given 3-weeks-on/1-week-off 28-day cycles. Eligible patients had solid tumors or B-cell lymphomas with no available standard treatment regimen.Forty-one (21...
Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitor therapy is showing marked efficacy in advanced non-small cell lung cancer (NSCLC). Meanwhile, it concomitant with distinctive immune-related adverse effects. We aim to describe the incidence of pneumonitis other rare but severe effects (IRAEs), as well treatment related deaths. In addition, we analyze differences between PD-1 PD-L1 inhibitors standard-of-care chemotherapy.PubMed was searched up 24 March 2017 for...
Expanded clinical experience with patients treated by pembrolizumab has accumulated. However, renal toxicities associated this anti-programmed cell death 1 agent are poorly described because kidney histology is rarely sought. As a nephrology referral centre, we aimed to describe the clinic-biological and histopathological characteristics of pembrolizumab-related nephropathy its response treatment.We conducted monocentric large case series study, including all pembrolizumab-treated cancer...
Anti-PD-(L)1 can provide overall survival (OS) benefits over conventional treatments for patients with many different cancer types. However, the long-term outcome of responding to these therapies remains unknown. This study is an exploratory that aimed describe anti-PD-(L)1 monotherapy across multiple types.Patients and Methods: Data from treated in a phase I trial at Gustave Roussy were retrospectively analyzed period 5 years. All types (n = 19) included. Clinical biological factors...